8-K: OS Therapies Completes Second Closing of Private Placement, Amends Purchase Agreement

OS Therapies finalizes a second closing of its private placement, securing additional funds and amending agreements to facilitate future closings.

Summary

• OS Therapies Incorporated completed the second closing of a private placement on January 10, 2025.
• This follows a previous announcement on December 30, 2024.
• The company amended its Securities Purchase Agreement and Registration Rights Agreement to accommodate additional closings.
• In the second closing, OS Therapies sold 263,250 units, each consisting of one share of Series A Preferred Stock and a warrant to purchase one share of common stock.
• Gross proceeds from the second closing totaled approximately $1,053,000 before deducting transaction fees.
• Brookline Capital Markets received a cash fee of $35,157, and Ceros Financial Services received $17,552 as placement agent fees.
• Brookline and Ceros also received warrants to purchase 8,788 and 4,388 shares of common stock, respectively.
• The company aims to file a registration statement with the SEC within 30 days of the second closing to cover resale of common stock underlying the Series A Preferred Stock and warrants.
• The company will use commercially reasonable efforts to have the registration statement declared effective within 45 days thereafter.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company successfully completed a second closing of its private placement, securing additional funding. However, there are restrictions on future stock issuances and the need to meet registration requirements, which temper the overall positive outlook.

Positives

• The successful second closing of the private placement provides OS Therapies with additional capital.
• Amending the Purchase Agreement allows for greater flexibility in raising capital through multiple closings.
• The company is taking steps to ensure the resale of shares by filing a registration statement with the SEC.

Risks

• The Purchase Agreement restricts the company from issuing additional common stock or securities convertible into common stock under certain conditions.
• The company is restricted from entering into variable rate transactions while investors hold warrants, subject to certain exceptions.
• Failure to meet the timelines for filing and effectiveness of the registration statement could negatively impact investors' ability to resell shares.

Future Outlook

The company intends to complete additional closings of the private placement, aiming to raise a total of $6 million to $10 million. They also plan to file a registration statement with the SEC to facilitate the resale of shares.

Industry Context

This announcement reflects a common practice in the biopharmaceutical industry, where companies often raise capital through private placements to fund research and development activities. The use of convertible preferred stock and warrants is also a typical structure for these types of financings.

Comparison to Industry Standards

• The terms of the private placement, including the unit price and warrant coverage, appear to be within the range of similar deals in the biopharmaceutical sector.
• Comparable companies often use similar financing structures to raise capital for clinical trials and drug development programs.
• The restrictions on issuing additional common stock and entering into variable rate transactions are also common features designed to protect investors.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares of Series A Preferred Stock and warrants.
• Investors in the private placement will have the opportunity to resell their shares once the registration statement is effective.
• The additional capital raised will support the company's research and development efforts, potentially benefiting patients in the long term.

Next Steps

• The company needs to file a registration statement with the SEC within 30 days of the second closing.
• The company needs to obtain effectiveness of the registration statement within 45 days thereafter.
• The company may conduct additional closings of the private placement before February 15, 2025.

Key Dates